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in pre-mobilization WBC counts and serum LDH levels.
However, the ratio of the LDH level immediately before
apheresis to the lowest one (“LDH-ratio”) were signiﬁcantly
lower in poor mobilizers than good mobilizers. Our ROC
analysis showed that the cut-off value of “LDH-ratio”was 1.75.
An elevation of serum LDH levels to reach “LDH-ratio”>1.75
were found to be a useful predictive factor for successful
CD34+ stem cell collection. The delay in reaching “LDH-
ratio”>1.75 may suggest that we should modify the mobili-
zation regimen by, for instance, adding prelixafor.Table 1
Pts’ characteristics
No. of Patients 55
Median age (range) 56(35-69)
Gender, male (%) 31(56)
Primary Disease
MM 19
NHL 26
HL 4
Others 6
Median WBC counts 103/mL (range) 2.1(1.5-3.2)
Median LDH Level IU/L (range) 196(145-445)
PBSC mobilization regimen
ESHAP 27
HD-CY 22
G-CSF alone 0
Others 6
MM indicates: multiple myeloma, NHL: non-hodgkin lymphoma, HL:
hodgkin lymphoma, HD-CY: high dose cyclophosphamide142
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Background: An HCT-CI score of 3 demonstrated signiﬁcant
differences in non-relapse mortality (NRM) and overall
survival independent from Karnofsky Performance Status
(KPS) in allogeneic HCT recipients. An HCT-CI score of 3 did
not predict NRM and survival in multiple myeloma (MM),
Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma
(NHL), but did predict signiﬁcant differences in the devel-
opment of grade 3-5 toxicities in NHL patients.
Purpose: Use of HCT-CI score to predict grade 3-5 toxicities
within 90 days post-autologous HCT in elderly patients.
Method: RetrospectivelyutilizedanHCT-CI scoreof3 topredict
grade 3-5 toxicities in autologous HCT patients  65 years in
a single HCT center in 2011. Outcome variables included
pulmonary (pneumonitisorﬁbrosis), gastrointestinal (diarrhea,
nausea ormucositis), neurologic (confusion), renal dysfunction
(increased creatinine), hepatic dysfunction (increased ALT/
AST), cardiovascular (decreased ejection fraction, and atrial or
ventricular arrythmias), fatigue and bone pain. Grading criteria
were based on the National Cancer Institute Common Termi-
nology Criteria Adverse Events version 4.0.
Results: The sample consisted of 37 autologous HCT recipi-
ents a mean of 67.4 years (range of 65-71), including 19
males (51.4%) and 18 females (48.6%) with the following
diagnoses MM (13), HL (1) NHL (21) and amyloidosis (2). Atthe time of transplant, 59.5% were not in complete remission.
KPS score was  80% in all patients and  90% in 33 (89.2%).
One patient expired 19 days post-HCT and two suffered
a relapse 55 and 107 days post-HCT, respectively. Each of
these three patients had HCT-CI scores 3. Utilizing HCT-CI
criteria, 23 (62.1%) had decreased pulmonary function, 6
(16.2%) had decreased cardiovascular function, 3 (8.1%) had
solid tumor history, and 3 (8.1%) had depression or anxiety.
Using an HCT-CI score of 3, 18 patients scoring  3
developed 44 grade 3-5 toxicities, while 19 patients with
a score < 3 developed 20 grade 3-5 toxicities (p ¼ .002).
ANCOVA multivariate analysis demonstrated that an HCT-CI
score of 3 can predict the number of grade 3-5 toxicities (p ¼
.044) independently from age, gender, KPS, diagnoses, and
pre-transplant disease status.
Conclusion: This retrospective study utilizing an HCT-CI
score of 3 predicted grade 3-5 toxicity in the ﬁrst 90 days
following HCT in elderly autologous HCT recipients inde-
pendent of KPS, diagnoses, disease status, age, and gender.
Thepredictive ability of theHCT-CI is superior toperformance
status. AddingHCT-CI to pre-HCTeligibility criteria for elderly
patients should be considered. Use of the HCT-CI may also be
utilized as part of pre-HCT counseling and education.143
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Recent experimental data in murine studies suggests that
hematopoietic stem cells (HSC) may not mobilize as well in
mice with diabetes (DM) compared to non-diabetic mice. We
performed a retrospective study of patients with and
without DM undergoing ﬁrst autologous stem cell mobili-
zation from 1/1/2009 to 1/1/2012 to compare efﬁciency of
mobilization and collection of CD34+ cells. Method of
mobilization was decided by the attending physician.
Chemotherapy and G-CSF were used if therapy or cytor-
eduction was necessary and, per institutional guideline,
cytokine only mobilization was G-CSF 10 ug/kg daily with
apheresis starting on day 5, and plerixafor 0.24 mg/kg was
added on day 4 if the peripheral blood CD34+ cells/ul was
< 15. A total of 343 pts underwent 362 attempts at collection
with 56 (15%) having type II DM. Failure to mobilize CD34
cells was deﬁned as never reaching 10 or greater peripheral
blood CD34+ cells/ul, or collecting less than 2 million CD34+
cells/kg. Both DM and non-DM pts required a median of 2
(range 1-4) days of apheresis for successful collection. The
mean total CD34+ cells/kg x 106 collected (std dev) was 6.12
(2.66) in DM pts vs 6.8 (3.58) in non-DM pts (p¼0.05). When
stratiﬁed by method of mobilization, the mean and median
total CD34+ cells collected were less, and the mean days of
apheresis were more in DM pts, but this did not reach
statistical signiﬁcance. Overall, 11/343 (3.2%) pts failed to
mobilize adequate CD34+cells and did not proceed to
autologous HSC transplant, with 4 of the 11 (36%) having DM.
Engraftment and day 100 transplant outcomes were not
different between pts with and without DM. In conclusion,
pts with DM may mobilize less CD34+ cells, but this appears
to be a small effect that is primarily overcome by current
methods of mobilization, with the majority of patients still
able to proceed to autologous HSC transplant. Larger studies
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different methods of mobilization or if long term transplant
outcomes are impacted.Table 1
N Censored 1 yr
survival
rate (%)
3 yr
survival
rate (%)
5 yr
survival
rate (%)
Median
(months)
95% CL
(months)
PFS 29 18 78 68 41 44.7 (17.3, NA)
OS-HSCT 29 20 81 66 66 112.0 (13.9, NA)
OS-DX 29 20 89 66 66 117.2 (18.7, NA)144
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The hematopoietic cell transplantation speciﬁc comorbidity
index (HCT-CI) has been proven to be a valuable tool in
allogeneic stem cell transplant (ASCT) recipients to predict
overall survival. There are few studies that use the HCT-CI for
evaluating autologous stem cell transplantation. Our insti-
tution performs autologous stem cell transplants in a variety
of settings, from completing the whole transplant process
inpatient to instituting their preparative regimen through
transplant and engraftment in the outpatient setting. We
retrospectively reviewed our experience of 250 autologous
stem cell transplants who had a diagnosis that included
Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's
Lymphoma, and Testicular Carcinoma that were either
treated inpatient for their hospital course or were prepared
in the outpatient setting and/or were discharged very early
in their transplant course (day-1 or within three days of their
autologous transplant). The median age of the inpatient
transplant group was 63.5 compared to the outpatient group
that was 58, P< 0.006. The average comorbidity index for the
inpatient group was 2.086 compared to the outpatient group
1.23, P < 0.001. In conclusion, our institution, using the HCT-
CI and age for autologous stem cell transplantation helps to
identify those candidates that are more successfully treated
in the inpatient setting and the outpatient setting. This study
was limited by its retrospective nature, small size and single
center experience. Prospective randomized studies are
needed to determine whether or not the HCT-CI in autolo-
gous stem cell transplantation is truly effective.145
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Background: There is no current standard of care for
patients with newly diagnosed AL amyloidosis. Autologous
HSCT is a potential option, but has been limited in its use due
to increasd treatment-relatedmortality (TRM) (38% from onerandomized study). Two large retrospective analyses showed
improved overall survival (OS) (70% at 4 yrs and 47% at 5 yrs)
of AL amyloid patients undergoing aHSCT compared to
control (40% at 4 yrs) with TRM of 13%.
Methods: We retrospectively analyzed the outcomes of 29
newly diagnosed AL amyloidosis patients who underwent
aHSCT between 10/1998 and 5/2012. Hematologic responses
were evaluated, along with post-transplant survival and
TRM. Progression-free survival (PFS) and (OS) were deter-
mined using the Kaplan-Meier method.
Results: Of the patients transplanted, 13 were female and 16
weremale.Median age at aHSCTwas 56 (range 26-71). Eleven
(38%) had involvement of at least 2 organs. Median brain
natriuretic peptide and troponin available in 20 patientswere
109 pm/ml (range 24-502) and 0.02ng/ml (range 0.01-1.17).
Twenty-onepatients (72%) receivedhighdoseMelphalan 200
mg/m2. Median CD34+ infused stem cells was 5.00 x 106/kg.
No patients received ﬁlgrastim or other colony stimulating
factor. Time to neutrophil and platelet engraftment were 12
and 17 days, respectively. Three months hematologic
response was available in 22 patients and showed complete
response, partial response, and stable disease in 15(68%), 2
(10%) and 5(22%), respectively. The 1, 3, and 5 year PFS were
78%, 68% and 41%, respectively. One, 3, and 5 year OS from
diagnosis and fromaHSCTwere81, 66, and66%and89, 66 and
66% respectively (Table 1). The 100-day and 1 year TRMwere
3.4% (1 patient) and 6.9% (2 patients), respectively.
Conclusion: Our results show that autologous HSCT is
a reasonable option for patients with newly diagnosed AL
amyloidosis. The 100 day and 1 year TRM compares favorably
to multiple myeloma patients undergoing autologous HSCT.146
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